Efeito do HER2 e do Cromossomo 17 no Resultado do Paciente no Ensaio Adjuvante Trastuzumabe N9831

Perez et al. (Ter,) estudaram esta questão.

www.synapsesocial.com/papers/69da4fde84371aa676a3d12e — DOI: https://doi.org/10.1200/jco.2009.26.2154

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. CALGB 150002: Correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2+ and HER2- metastatic breast cancer (MBC)· 2007 · 38 citations
2. Reproducibility of LSI HER-2/neu SpectrumOrange and CEP 17 SpectrumGreen Dual Color deoxyribonucleic acid probe kit. For enumeration of gene amplification in paraffin-embedded specimens: a multicenter clinical validation study.· 1998 · 27 citations
3. Duplication of Chromosome 17 CEP Predicts for Anthracycline Benefit: A Meta-Analysis of 4 Trials.· 2009 · 3 citations
4. Gene copy numbers of HER family in breast cancer· 2007 · 26 citations
5. Do the ASCO/CAP 2007 HER2 Testing Guidelines Improve Prediction of Benefit to Adjuvant Trastuzumab?: Data from North Central Cancer Treatment Group N9831 Adjuvant Trial.· 2009 · 5 citations